Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 6/20 | 0.44 |
| ▸ | FPR3 | P25089 | 5/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CTSE | P14091 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18226512 | 0.92 | RORC (0.53) | RORCJAK2JAK1FPR2FPR3 | |
| SCHEMBL16936273 | 0.92 | RORC (0.53) | RORCJAK2JAK1FPR2FPR3 | |
| SCHEMBL16936274 | 0.92 | RORC (0.53) | RORCJAK2JAK1FPR2FPR3 | |
| SCHEMBL4630326 | 0.86 | MEN1 (0.55) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL29087373 | 0.86 | RORC (0.50) | RORCJAK2JAK1TSHRALOX15 | |
| SCHEMBL10324681 | 0.86 | TSHR (0.56) | RORCJAK2JAK1GPR119TSHR | |
| SCHEMBL26372776 | 0.85 | GPR119 (0.54) | JAK2JAK1GPR119TSHRALOX15 | |
| SCHEMBL13908097 | 0.85 | BACE1 (0.55) | GPR119TSHRCTSDCTSEBACE1 | |
| SCHEMBL16764525 | 0.85 | RORC (0.53) | RORCJAK2JAK1FPR2FPR3 | |
| SCHEMBL1199600 | 0.85 | RORC (0.51) | RORCJAK2JAK1FPR2FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492181-B2 | Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4509500-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | Sichuan Huiyu Pharmaceutical Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| CN-119173510-A | Hydroxy amide derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-115335369-B | GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023222115-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | 四川汇宇制药股份有限公司 | 2023-11-23 | — | — | WO | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| CN-115335369-A | GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021126693-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3096754-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9708336-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-17 | — | — | US | disclosed |
| EP-1919875-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | Astex Therapeutics Limited (GB) | 2008-05-14 | — | — | EP | disclosed |
| WO-2006136829-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC1R, MC3R, MC2R | RORC 437/4885JAK2 701/4885JAK1 2740/4885 |
| US-12492181-B2 | Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC1R, MC3R, MC2R | RORC 437/4885JAK2 701/4885JAK1 2740/4885 |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC5 | RORC 816/4885JAK2 3042/4885JAK1 4134/4885 |
| US-20160333021-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, GAA | RORC 1415/4885JAK2 4484/4885JAK1 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.